Eyenovia, Inc. (EYEN) Covered Calls
You can sell covered calls on Eyenovia, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for EYEN (prices last updated Fri 4:16 PM ET):
| Eyenovia, Inc. (EYEN) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 0.11 | 0.00 | 0.10 | 0.11 | 29.5M | - | 0.0 |
| Covered Calls For Eyenovia, Inc. (EYEN) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Dec 20 | 0.5 | 0.00 | 0.11 | 0.0% | 0.0% | |
| Jan 17 | 0.5 | 0.00 | 0.11 | 0.0% | 0.0% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, through its proprietary delivery technology, is developing smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration. Eyenovia, Inc. focuses on advancing its MicroLine program for the improvement in near vision in patients with presbyopia in Phase III development. Its other product candidates include MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of red eye and itch relief lubrication; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
| Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
| 2. | SPY covered calls | 7. | XLF covered calls | 2. | CRVS covered calls | |
| 3. | EEM covered calls | 8. | TLT covered calls | 3. | APLT covered calls | |
| 4. | FXI covered calls | 9. | KWEB covered calls | 4. | ANAB covered calls | |
| 5. | IWM covered calls | 10. | AAPL covered calls | 5. | IREN covered calls | |
Want more examples? EYE Covered Calls | EYPT Covered Calls
